Mutant Calreticulin-Specific Monoclonal Antibody, INCA033989, is Well Tolerated and Achieves Robust Spleen, Anemia, and Molecular Responses in Patients With Myelofibrosis (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-554; Location: LEVEL 3, HALL B3; P1 | "INCA033989 alone or with ruxolitinib showed favorable safety in patients with MF relapsed/resistant/intolerant/ineligible for JAK inhibitor treatment, or suboptimal response to ruxolitinib. Robust spleen, symptom, and anemia responses were observed and correlated with mutCALR reduction. AE: adverse event; DLT: dose-limiting toxicity; IgG: immunoglobulin; IWG-ELN: International Working Group–European LeukemiaNet; JAK: Janus kinase; MF: myelofibrosis; MPN-SAF: Myeloproliferative Neoplasm Symptom Assessment Form; MTD: maximum tolerated dose; mutCALR: calreticulin mutations; SV: spleen volume; TEAE: treatment-emergent adverse event; TSS: total symptom score; VAF: variant allele frequency."
Clinical • Essential Thrombocythemia • Hematological Malignancies • Leukemia • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • CALR
|
|
Tania Jain MBBS 1; Vikas Gupta MD 2; Haifa Kathrin Al-Ali 3; Haris Ali MD 4; John Mascarenhas MD 5; Francesco Passamonti MD 6; Aaron Gerds MD 7; Sanjay Mohan MD 8; Francesca Palandri MD PhD 9; Bethan Psaila PhD 10; Raajit Rampal MD PhD 11; William Shomali MD 12; David M Ross PhD 13; Vincent Ribrag MD 14; Terrence Bradley MD 15; Joan How MD 16; Steffen Koschmieder 17; Caroline McNamara MD 18; Andrew Perkins PhD 19; Abdulraheem Yacoub MD 20; Claire Harrison MDDM 23
|